In the Treatment of Alzheimer’s Disease, Polypharmacy Increases Across Lines of Therapy, According to New Analysis from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one ...

(CBS/AP) Alzheimer's disease patients who are taking a commonly prescribed drug can still benefit from it after they progress to moderate-to-severe illness, when it can be tough to tell whether it's ...

Alzheimer’s medications typically used only in early stages of the disease can be more useful in later, more severe stages of dementia than previously thought, a new study suggests. British ...

Alzheimer’s disease patients who are taking a commonly prescribed drug can still benefit from it after they progress to moderate-to-severe illness, when it can be tough to tell whether it’s doing any ...

A radiant, smiling grandpa is frolicking with his grandchildren on a sunny, wildflower-covered hillside. In the television version, serene violin music wafts in the background. This is the unrealistic ...

Actavis ($ACT) hit a hurdle for Alzheimer's blockbuster Namenda when a court nixed its plot to force patients over to a new, long-acting formula. But as the Dublin ...

Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer's ...

Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer's ...

NEW YORK (AP) -- Alzheimer's disease patients who are taking a commonly prescribed drug can still benefit from it after they progress to moderate-to-severe illness, when it can be tough to tell ...